Research Use Only — Not for Human or Veterinary Use
BPC-157 10mg is supplied exclusively for in vitro research and pre-clinical laboratory investigation. It is not approved for therapeutic use in humans or animals by the MHRA, FDA, or any other regulatory authority. Purchase confirms the buyer is a qualified researcher operating within an institutional or commercial laboratory setting.
BPC-157 (Body Protection Compound-157) — Research Grade, 10 mg Lyophilised Vial
BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a partial sequence of human gastric juice protein BPC. The full sequence — Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV) — was first characterised by Sikiric and colleagues in the early 1990s and has since become one of the most extensively investigated synthetic peptides in pre-clinical regenerative biology. Each 10 mg vial supplied by AbsoluteBioLab contains lyophilised BPC-157 acetate salt, manufactured to research-grade standards and verified by HPLC and mass spectrometry prior to dispatch.
Analytical Specification
| Parameter | Specification |
|---|---|
| Sequence (single-letter) | GEPPPGKPADDAGLV |
| Molecular Formula | C62H98N16O22 |
| Molecular Weight | 1,419.55 Da |
| CAS Number | 137525-51-0 |
| Salt Form | Acetate |
| Physical Form | White to off-white lyophilised powder |
| Purity (HPLC) | ≥99.0% |
| Identity Confirmation | ESI-MS (electrospray ionisation mass spectrometry) |
| Vial Fill | 10 mg per vial |
| Sterility | Non-sterile research reagent |
Storage and Transport Conditions
| Condition | Specification |
|---|---|
| Lyophilised (sealed vial) | −20 °C, protected from light and moisture |
| Reconstituted solution | 2–8 °C; use within 28 days; avoid repeated freeze-thaw cycles |
| Transit | Dispatched with cold-chain packaging; ambient transit does not compromise lyophilised integrity for standard UK delivery windows |
| Solubility | Freely soluble in sterile water or bacteriostatic water for injection (research grade); soluble in dilute acetic acid (0.1–1%) |
Batch Documentation and Quality Assurance
Every batch of BPC-157 10mg supplied by AbsoluteBioLab is accompanied by a Certificate of Analysis (CoA) confirming HPLC purity ≥99.0% and ESI-MS identity. Batch-specific CoA documents are available through the AbsoluteBioLab CoA Portal. Our quality framework and analytical methodology are described in full on the HPLC Purity & Peptide Testing page. Researchers requiring additional analytical data — including TFA content, endotoxin testing, or residual solvent profiles — should contact the laboratory team directly.
Research Context: Signalling Pathways and Pre-Clinical Evidence
BPC-157 has been the subject of sustained pre-clinical investigation since the early 1990s, with a body of evidence now spanning over 500 published studies across rodent and in vitro models. The mechanistic picture that has emerged positions BPC-157 as a pleiotropic cytoprotective agent operating through several overlapping molecular pathways.
The most thoroughly characterised mechanism involves the VEGFR2–Akt–eNOS signalling axis. Hsieh et al. (2017) demonstrated that BPC-157 promotes VEGFR2 internalisation and upregulates its expression in vascular endothelial cells, activating downstream Akt-eNOS phosphorylation and driving measurable increases in vessel density in both chick chorioallantoic membrane assays and rat hind-limb ischaemia models.[1] A subsequent study by the same group (2020) further resolved the vasomotor dimension of this pathway, showing that BPC-157 produces endothelium-dependent vasodilation through Src-Caveolin-1-eNOS signalling — a finding with direct relevance to microvascular perfusion research.[2]
A 2026 study by Zhang et al. published in Cell Communication and Signaling identified a previously unknown molecular mechanism: BPC-157 engages the E3 ubiquitin ligase adaptor FBXO22 via its proline residue at position 3, suppressing ubiquitination and proteasomal degradation of the transcription factor BACH1. The resulting BACH1 stabilisation enhances endothelial cell proliferation and tube-forming capacity, establishing the BPC157–FBXO22–BACH1 axis as a distinct proangiogenic pathway.[3]
Beyond angiogenesis, BPC-157 has demonstrated consistent effects on connective tissue repair. Gwyer et al. (2019) reviewed the available evidence for tendon, ligament, and skeletal muscle healing, noting that all studies to date have reported positive outcomes in rodent models, with BPC-157 accelerating functional restoration in hypovascular tissues — the class of tissue most resistant to conventional healing strategies.[4] The 2025 systematic review by Vasireddi et al. in HSS Journal — which screened 544 articles and included 36 studies — confirmed that BPC-157 enhances growth hormone receptor expression, reduces inflammatory cytokines, and improves biomechanical outcomes in muscle, tendon, ligament, and bone injury models, while noting that the compound is metabolised in the liver with a plasma half-life of under 30 minutes and cleared renally.[5]
The pharmacokinetic profile was formally characterised by He et al. (2022) in the first published ADME study of BPC-157, conducted in rats and beagle dogs. Following intramuscular administration, the elimination half-life was confirmed at under 30 minutes across all dose levels, with linear pharmacokinetics and absolute bioavailability of 14–19% in rats and 45–51% in dogs. The compound was rapidly metabolised into small peptide fragments and individual amino acids, with excretion primarily via urine and bile.[6] This short plasma half-life contrasts with prolonged biological effects lasting hours to days — a pharmacokinetic–pharmacodynamic disconnect discussed in depth by Mateescu et al. (2026) in their biopharmaceutical review, which identifies this as one of the central formulation challenges for any future clinical programme.[7]
Researchers working with BPC-157 in the context of musculoskeletal biology may also find the TB-500 10mg product relevant, given the complementary but mechanistically distinct tissue repair profiles of the two peptides. A detailed structural and functional comparison is available in the TB-500 vs Thymosin Beta-4 guide.
Reconstitution and Handling
BPC-157 lyophilised powder reconstitutes readily in sterile water or bacteriostatic water for injection (research grade). The peptide is freely soluble at standard laboratory working concentrations. Researchers should note that the lyophilised form is considerably more stable than the reconstituted solution; once reconstituted, the working solution should be stored at 2–8 °C and used within 28 days. Repeated freeze-thaw cycles of the reconstituted solution should be avoided, as these accelerate peptide degradation. A full reconstitution protocol — including solvent selection rationale, aliquoting strategy, and concentration calculations — is available in the BPC-157 Reconstitution & Solvent Stability Guide. Compatible laboratory consumables, including bacteriostatic water and sterile vials, are available in the Accessories category.
Analytical Note — AbsoluteBioLab Quality Team
In routine incoming QC, we observe that BPC-157 lyophilisates from different synthesis batches can vary in reconstitution behaviour — specifically, the time to full dissolution at room temperature. This is typically a function of residual moisture content in the lyophilised cake rather than peptide purity. Batches with a denser, more compressed lyophilised cake may require gentle vortexing for 30–60 seconds to achieve complete dissolution. We do not recommend sonication, as this can introduce mechanical stress to the peptide backbone. If turbidity persists after vortexing, warming the solution briefly to 25–30 °C whilst continuing to mix will resolve it in the majority of cases. All batches are HPLC-verified at ≥99.0% purity before dispatch; reconstitution behaviour does not affect analytical specification.
Regulatory and Compliance Status
BPC-157 has no approved therapeutic indication in any jurisdiction. It is not licensed by the MHRA, FDA, or EMA for human or veterinary use. The World Anti-Doping Agency (WADA) temporarily listed BPC-157 as a prohibited substance in 2022 under Class S0 (Unapproved Substances); it was subsequently removed from the WADA Prohibited List, though researchers affiliated with sporting organisations should verify the current status with their relevant body. This product is supplied strictly as a research reagent for pre-clinical and in vitro investigation. It is not intended for diagnostic, therapeutic, or prophylactic use in humans or animals.
Frequently Asked Questions
What purity standard does AbsoluteBioLab apply to BPC-157?
Each batch is tested by reverse-phase HPLC and must achieve ≥99.0% purity before release. Identity is confirmed by ESI-MS. Batch-specific CoA documents are available through the CoA Portal.
What is the recommended storage condition for the lyophilised vial?
Sealed lyophilised vials should be stored at −20 °C, protected from light and moisture. Under these conditions, the lyophilised powder is stable. Once reconstituted, the working solution should be held at 2–8 °C and used within 28 days. Repeated freeze-thaw cycles of the reconstituted solution should be avoided.
Is BPC-157 soluble in water?
Yes. BPC-157 is freely soluble in sterile water and bacteriostatic water at standard research working concentrations. It is also soluble in dilute acetic acid (0.1–1% v/v) if required. Full reconstitution guidance is available in the BPC-157 Reconstitution Guide.
What is the molecular weight of BPC-157?
The molecular weight of BPC-157 (free base, acetate salt) is 1,419.55 Da. The molecular formula is C62H98N16O22 and the CAS number is 137525-51-0.
How does BPC-157 differ from TB-500?
BPC-157 and TB-500 are structurally unrelated peptides with distinct mechanisms of action. BPC-157 operates primarily through the VEGFR2–Akt–eNOS and FBXO22–BACH1 axes, whilst TB-500 (a fragment of Thymosin Beta-4) promotes actin polymerisation and cell migration via G-actin sequestration. A detailed comparison is available in the TB-500 vs Thymosin Beta-4 structural guide.
Is a Certificate of Analysis available for each batch?
Yes. Batch-specific CoA documents — including HPLC chromatograms and MS data — are available through the AbsoluteBioLab CoA Portal. The CoA is also included with each order.
Can BPC-157 be used in cell culture experiments?
BPC-157 is a non-sterile research reagent. Researchers intending to use it in cell-based assays should apply appropriate sterile filtration (0.22 µm) to the reconstituted solution prior to use. It is the researcher’s responsibility to validate the suitability of the reagent for their specific assay conditions.
References
- Hsieh M-J, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017;95(3):323–333. doi:10.1007/s00109-017-1570-y
- Hsieh M-J, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020;10(1):14488. doi:10.1038/s41598-020-71580-9
- Zhang J, et al. BPC157 drives angiogenesis through FBXO22-dependent stabilization of BACH1. Cell Commun Signal. 2026;24(1):112. doi:10.1186/s12964-026-01987-x
- Gwyer D, et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153–159. doi:10.1007/s00441-019-03016-8
- Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. doi:10.1177/15563316251324567
- He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs. Front Pharmacol. 2022;13:839685. doi:10.3389/fphar.2022.839685
- Mateescu D-M, et al. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. 2026;18(4):123. doi:10.3390/pharmaceutics18040123
Reviews
There are no reviews yet.